PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2020.135020215341033-1041Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean PopulationHo Cheol Kim, Wonjun Ji, Jae Cheol Lee, Hyeong Ryul Kim, Si Yeol Song, Chang-Min Choi, , http://e-crt.org/upload/pdf/crt-2020-1350.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2020.1350, http://e-crt.org/upload/pdf/crt-2020-1350.pdf
Lung Cancer10.1016/s0169-5002(20)30143-42020139S51Real-world data of using durvalumab in stage III non-small cell lung cancer (NSCLC): West Midlands experienceA. Jegannathenhttps://api.elsevier.com/content/article/PII:S0169500220301434?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220301434?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2012.06.00520131411-5Improving Outcomes for High-Risk Patients With Early-Stage Non–Small-Cell Lung Cancer: Insights from Population-Based Data and the Role of Stereotactic Ablative RadiotherapyDavid A. Palma, Suresh Senanhttps://api.elsevier.com/content/article/PII:S1525730412001362?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730412001362?httpAccept=text/plain
Clinical Lung Cancer10.3816/clc.2007.n.031200788478-482Prognostic Factors in Stage III Non–Small-Cell Lung CancerFoluso O. Ademuyiwa, Cynthia S. Johnson, Angela S. White, Timothy E. Breen, Jayme Harvey, Marcus Neubauer, Nasser H. Hannahttps://api.elsevier.com/content/article/PII:S1525730411708245?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411708245?httpAccept=text/plain
Clinical Lung Cancer10.1016/s1525-7304(11)70694-5200674276-278Prophylactic Cranial Irradiation Versus Observation in Stage III Non–Small-Cell Lung CancerElizabeth Gorehttps://api.elsevier.com/content/article/PII:S1525730411706945?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411706945?httpAccept=text/plain
Clinical Lung Cancer10.1016/s1525-7304(11)70793-819991168-69Commentary on “Prognostic Markers in Resected Stage I and II Non–Small-Cell Lung Cancer Patients”David H. Harpolehttps://api.elsevier.com/content/article/PII:S1525730411707938?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411707938?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2022.02.0022022234364-373Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa – KINDLE StudyA.R. Jazieh, E. Kaytan Sağlam, H.C. Önal, Y. Abdelkader, R. Gaafar, E. Dawoud, M. Nassar, D. Alshorbagy, H. El Ashry, M. Elsayedhttps://api.elsevier.com/content/article/PII:S152573042200016X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S152573042200016X?httpAccept=text/plain
Clinical Lung Cancer10.3816/clc.2002.s.01820024S21-S25Irinotecan Combined with Radiation Therapy for Patients with Stage III Non—Small-Cell Lung Cancer: Current TrialsNagahiro Saijohttps://api.elsevier.com/content/article/PII:S1525730411705599?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411705599?httpAccept=text/plain
Clinical Oncology10.1016/j.clon.2016.04.04520162810639-647Application of Guideline Recommended Treatment in Routine Clinical Practice: A Population-based Study of Stage I–IIIB Non-small Cell Lung CancerK.J. Duggan, J. Descallar, S.K. Vinodhttps://api.elsevier.com/content/article/PII:S0936655516300796?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0936655516300796?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2019.06.0232019206e619Comment on the data of the article titled “Second Primary Non–Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients”Junmiao Wenhttps://api.elsevier.com/content/article/PII:S1525730419301743?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730419301743?httpAccept=text/plain